Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 19, Number 8—August 2013


Macrolide Resistance of Mycoplasma pneumoniae, South Korea, 2000–2011

Ki Bae Hong, Eun Hwa ChoiComments to Author , Hoan Jong Lee, Seong Yeon Lee, Eun Young Cho, Jae Hong Choi, Hyun Mi Kang, Jina Lee, Young Min Ahn, Yeon-Ho Kang, and Joon-Ho Lee
Author affiliations: Seoul National University Hospital, Seoul, South Korea (K.B. Hong, E.H. Choi, H.J. Lee, S.Y. Lee, E.Y. Cho, J.H. Choi, H.M. Kang); Seoul National University College of Medicine, Seoul (E.H. Choi, H.J. Lee); Seoul National University Bundang Hospital, Seongnam, South Korea (J. Lee); Seoul Eulji Hospital, Seoul (Y.M. Ahn); Korea Centers for Disease Control and Prevention, Seoul (Y.-H. Kang); Kangwon National University Hospital, Chuncheon, South Korea (J.-H. Lee)

Main Article

Table 1

MICs of macrolide antimicrobial drugs for 123 Mycoplasma pneumoniae strains in a study of macrolide resistance, South Korea, 2000–2011*

Macrolides Strains with 23S rRNA mutation, n = 69
Strains without 23S rRNA mutation, n = 54
Range MIC50 MIC90 Range MIC50 MIC90
Erythromycin 2 to >128 16 128 0.001 to 0.004 0.001 0.002
Clarithromycin 8 to >128 64 128 0.001 to 0.002 0.001 0.002
Roxithromycin 0.008 to 128 8 32 0.001 to 0.008 0.001 0.004
Azithromycin 1 to 64 8 16 0.001 to 0.001 0.001 0.001
Josamycin 1 to 8 4 8 0.001 to 0.016 0.001 0.008

*MIC50 and MIC90 are minimum inhibitory concentrations at which 50% and 90% of the isolates, respectively, were inhibited by the drug. In each instance, p<0.0001.

Main Article

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO